Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room - Transparency notification FMR LLC.


[09/08/2021 | 20:07]

** Transparency notification FMR LLC.

=C2=B7 Notification referring to situation on 30 July 2021
=C2=B7 Threshold crossed: 5%
=C2=B7 Latest holding: 3.63 %

Brussels (Belgium), 9 August 2021 =E2=80=93 20:00 (CEST) =E2=80=93 regulate=
d information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large =
shareholdings, UCB=C2=A0SA/NV announces that it has received a transparency=
notification from FMR LLC. (having its registered office at The Corporatio=
n Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware=
19801, U.S.A.), on 5 August 2021.

FMR LLC., has notified that, following an acquisition of UCB=C2=A0shares wi=
th voting rights by its affiliates, its holding in UCB shares with voting r=
ights has increased and has crossed for the first time the 5% threshold on =
30 July 2021.

On 30 July 2021, FMR LLC. (taking into account the holding of its affiliate=
s) owned 9 728 407 UCB=C2=A0shares with voting rights, representing 5.00% o=
f the total number of shares issued by the company (194 505 658).

1. Content of the notification

=C2=B7 Reason for the notification: Acquisition or disposal of voting secur=
ities or voting rights.
=C2=B7 Notification by: A parent undertaking or a controlling person.
=C2=B7 Persons subject to the notification requirement:


=C2=B7 Date on which the threshold is crossed: 30 July 2021.
=C2=B7 Threshold crossed (in %): 5%.
=C2=B7 Denominator: 194 505 658.
=C2=B7 Notified details:


=C2=B7 Chain of controlled undertakings through which the holding is effect=
ively held:

Further information

This press release and the detailed transparency notification are available=
on UCB=C2=A0SA/NV=E2=80=99s website via the following link (https://www.uc=
b.com/investors/UCB-shareholders/Transparency-notifications) .

An updated overview of the UCB=C2=A0SA/NV large shareholdings will be avail=
able on UCB=C2=A0SA/NV=E2=80=99s website via the following link (https://ww=
w.ucb.com/investors/UCB-shareholders) .
Investor Relations
Antje Witte
Investor Relations, UCB
T +32 2 559 94 14
Corporate Communications
Laurent Schots
Media Relations, UCB
About UCB

UCB, Brussels, Belgium (www.ucb.com (http://www.ucb.com) ) is a global biop=
harmaceutical company focused on the discovery and development of innovativ=
e medicines and solutions to transform the lives of people living with seve=
re diseases of the immune system or of the central nervous system. With app=
roximately 8 400 people in nearly 40 countries, the company generated reven=
ue of =E2=82=AC 5.3 billion in 2020. UCB is listed on Euronext Brussels (sy=
mbol: UCB). Follow us on Twitter: @UCB_news

210809 - Transparency notification press release FMR LLC (https://mb.cision=
.com/Public/18595/3393930/aba1c576d6af70be.pdf) GenericFile
210809 - Notification de transparence comm de presse FMR LLC (https://mb.ci=
sion.com/Public/18595/3393930/aeea62953b5b0764.pdf) GenericFile
210809 - Transparantieverklaring persbericht FMR LLC (https://mb.cision.com=
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x79015x1x6868579x24000=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=